<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902301</url>
  </required_header>
  <id_info>
    <org_study_id>Project PCOS</org_study_id>
    <nct_id>NCT03902301</nct_id>
  </id_info>
  <brief_title>Lactobacillus Rhamnosus and PCOS Treatment</brief_title>
  <acronym>ProjectPCOS</acronym>
  <official_title>The Effect of Lactobacillus Rhamnosus Supplementation on Body Mass, Hyperandrogenism and Insulin Resistance in Overweight and Obese Polycystic Ovary Syndrome Women - Randomized Nutritional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Life Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of Lactobacillus rhamnosus supplementation on body weight, hyperandrogenism and
      insulin resistance in overweight and obesity women with Polycystic Ovary Syndrome will be
      analysed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>20 weeks</time_frame>
    <description>Fasting insulin concentration (uU/ml) will be measured before and after 2 hours of 75g glucose drink. Insulin resistance will be measured before and after 20 weeks of the intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose test OGTT</measure>
    <time_frame>20 weeks</time_frame>
    <description>Fasting glucose concentration (mg/dL) will be measured before and after 2 hours of 75g glucose drink. OGTT will be measured before and after 20 weeks of the intervention. Fating glucose and fasting insulin concentrations will be combined to report HOMA-IR index (homeostatic model assessment of insulin resistance).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testosterone</measure>
    <time_frame>20 weeks</time_frame>
    <description>Testosterone (ng/mL) concentrations will measured at baseline and after 20 weeks of the intervention. Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DHEA-SO4</measure>
    <time_frame>20 weeks</time_frame>
    <description>DHEA-SO4 (umol/L) concentrations will measured at baseline and after 20 weeks of the intervention. Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SHBG</measure>
    <time_frame>20 weeks</time_frame>
    <description>SHBG (nmol/L) concentrations will measured at baseline and after 20 weeks of the intervention. Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free androgen index FAI</measure>
    <time_frame>20 weeks</time_frame>
    <description>Results of testosterone level and SHBG level will be combined to report FAI index (index of free androgen).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>20 weeks</time_frame>
    <description>Body weight (kg) will be assessment at baseline and after 20 weeks of the intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body height</measure>
    <time_frame>Baseline</time_frame>
    <description>Body height (cm) will be assessment at baseline of the intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition</measure>
    <time_frame>20 weeks</time_frame>
    <description>Fat mass (%), fat free mass (%) will be assessment at baseline and after 20 weeks of the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipid profile: cholesterole</measure>
    <time_frame>20 weeks</time_frame>
    <description>Cholesterole (mg/dL) will be measured at baseline and after 20 weeks of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid profile: triglicerydes</measure>
    <time_frame>20 weeks</time_frame>
    <description>Triglicerydes (mg/dL) will be measured at baseline and after 20 weeks of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid profile: high density lipoprotein</measure>
    <time_frame>20 weeks</time_frame>
    <description>High density lipoprotein HDL (mg/dL) will be measured at baseline and after 20 weeks of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid profile: low density lipoprotein</measure>
    <time_frame>20 weeks</time_frame>
    <description>Low density lipoprotein LDL (mg/dL) will be measured at baseline and after 20 weeks of the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of qualitative and quantitative of the microbiome</measure>
    <time_frame>20 weeks</time_frame>
    <description>Qualitative and quantitative determination of the composition of gut microbiota will be assessment at baseline and after 20 weeks of the intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Hyperandrogenism</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dietary group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A diet based on general recommendations for people with insulin resistance for 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus rhamnosus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus group</intervention_name>
    <description>Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).</description>
    <arm_group_label>Lactobacillus rhamnosus group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary group</intervention_name>
    <description>Nutritional intervention focused on the treatment of insulin resistance (35 subjects).</description>
    <arm_group_label>Dietary group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  patients diagnosed with PCOS,

          -  BMI&gt; 28 kg/m2 (overweight or obesity),

          -  patients not participating in other similar research programs at the same time,

          -  no previous operations on ovaries such as: laparoscopy, ovarian cautery etc.,

          -  written agreement to take part in the research.

        Exlusion criteria:

          -  the use of antibiotics or probiotics within 6 months before the start of the
             experiment,

          -  the use of pharmacological agents or hormones that may affect the course of the
             menstrual cycle or metabolic rate within 3 months,

          -  the use of medicament that may affect on carbohydrate metabolism within 4 weeks,

          -  failure to comply with dietary recommendations established during the nutritional
             intervention,

          -  the use of weight loss supplements during the study,

          -  clinical diagnosis of digestive disease (for example: irritable bowel syndrome,
             ulcerative colitis, Crohn's disease, celiac disease),

          -  pregnancy and breast feeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Poznan University of Life Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>60-624</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Łagowska, PhD</last_name>
      <phone>+48618487335</phone>
      <email>karolina.lagowska@up.poznan.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Life Sciences</investigator_affiliation>
    <investigator_full_name>Karolina Łagowska</investigator_full_name>
    <investigator_title>Principal Investigator (dr inż)</investigator_title>
  </responsible_party>
  <keyword>Lactobacillus rhamnosus</keyword>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>nutrition intervention</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

